Specific Interaction of DARPin with HIV-1 CA\textsubscript{NTD} Disturbs the Distribution of Gag, RNA Packaging, and Tetraspanin Remodelling in the Membrane

Sutpirat Moonmuang\textsuperscript{1,2,3}, Rawiwan Maniratanachote \textsuperscript{3}, Paninee Chetprayoon \textsuperscript{3}, Kanokporn Sornsuwan \textsuperscript{1}, Weeraya Thongkum \textsuperscript{1,4}, Koollawat Chupradit \textsuperscript{1,5} and Chatchai Tayapiwatana \textsuperscript{1,2,4,*}

\textsuperscript{1} Center of Biomolecular Therapy and Diagnostic, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand; sutpirat.m@cmu.ac.th (S.M.); kanokporn.sornsuwan@cmu.ac.th (K.S.); weeraya.t@cmu.ac.th (W.T.); koollawat.chu@mahidol.ac.th (K.C.)
\textsuperscript{2} Department of Medical Technology, Division of Clinical Immunology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
\textsuperscript{3} Toxicology and Bio Evaluation Service Center (TBES), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand; rawiwan.man@nstda.or.th (R.M.); paninee.che@nstda.or.th (P.C.)
\textsuperscript{4} Center of Innovative Immunodiagnostic Development, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
\textsuperscript{5} Siriraj Center for Regenerative Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

* Correspondence: chatchai.t@cmu.ac.th

Abstract: A designed repeat scaffold protein (Ank\textsubscript{GAG1D4}) recognizing the human immunodeficiency virus-1 (HIV-1) capsid (CA) was formerly established with antiviral assembly. Here, we investigated the molecular mechanism of Ank\textsubscript{GAG1D4} function during the late stages of the HIV-1 replication cycle. By applying stimulated emission-depletion (STED) microscopy, Gag polymerisation was interrupted at the plasma membrane. Disturbance of Gag polymerisation triggered Gag accumulation inside producer cells and trapping of the CD81 tetraspanin on the plasma membrane. Moreover, reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) experiments were performed to validate the packaging efficiency of RNAs. Our results advocated that Ank\textsubscript{GAG1D4} interfered with the Gag precursor protein from selecting HIV-1 and cellular RNAs for encapsidation into viral particles. These findings convey additional information on the antiviral activity of Ank\textsubscript{GAG1D4} at late stages of the HIV-1 life cycle, which is potential for an alternative anti-HIV molecule.

Keywords: HIV-1; Gag polyprotein; virus assembly inhibitor; ankyrin; tetraspanin

1. Introduction

The human immunodeficiency virus-1 (HIV-1) group-specific antigen (Gag) polyprotein is the precursor of capsid (CA) protein (the target of Ank\textsuperscript{GAG1D4}) and is encoded by genomic RNA (gRNA; also known as full-length (FL) RNA). Gag plays an important role in viral assembly and RNA recruitment for HIV-1. Gag contains four major domains: matrix (MA), CA, nucleocapsid (NC), and p6, in addition to two spacer peptides, SP1 and SP2. Gag is myristoylated at the N-terminus of MA and contains a highly basic region (HBR) involved in targeting Gag to phosphatidylinositol 4,5-bisphosphate, PI (4,5) P2 and anchoring it to the inner leaflet of the host cell plasma membrane (PM), where viral assembly takes place [1,2].

The Gag precursor promotes HIV-1 FL RNA dimerisation in the cytoplasm and specifically targets the dimeric FL RNA to virus-assembly sites at the PM [3,4]. The virus-assembly site is composed of thousands of Gag polyprotein molecules, hundreds of Gag–polymerase (Pol) precursor proteins, 8–10 envelope (Env) protein trimers, and dimeric FL RNA [5,6].
Subsequently, the Gag polyprotein recruits the cellular endosomal sorting complexes required for transport (ESCRT) machinery for budding and membrane scission for viral particle egress [7].

After synthesis, the primary FL HIV-1 transcript mediates several key roles in viral replication. Not only being a precursor of spliced mRNA synthesis, it also acts as a template for viral protein production and as a genome incorporated into viral progeny [8]. The Gag precursor protein must select FL HIV-1 RNA from numerous cellular and viral spliced RNAs, including multiply spliced (MS) and singly spliced viral mRNAs (with env mRNA being the major determinant) [9]. However, spliced viral RNAs can be selected due to the presence of an internal loop and lower part of stem-loop 1 (SL1): in that context, the Gag precursor protein recognises FL HIV-1 RNA with higher affinity than spliced RNAs [10]. In addition to viral RNAs, retroviruses package significant amounts of cellular RNAs randomly package significant amounts of cellular RNAs including Pol-III RNA species such as 7SL and U6 RNAs [11,12]. Indeed, cellular 7SL RNA, a component of signal-recognition particles (SRPs) involved in protein translocation across the endoplasmic reticulum [11,12] and U6 spliceosomal RNA [11] are both enriched in HIV-1 particles.

During HIV-1 assembly and release, cellular tetraspanins are recruited by Gag to egress sites [13]. Tetraspanins belong to a large family of membrane glycoproteins characterised by four transmembrane proteins that are widely expressed in human cells. They play many essential roles in cellular and infectious processes [14,15]. Tetraspanins can form dynamic networks of interacting proteins at the PM by interacting with each another and with other transmembrane proteins, and such networks are referred to as tetraspanin-enriched microdomains (TEMs) [16,17]. Data from several studies showed that tetraspanins (mostly CD9, CD63, CD82, and CD81) can interact with HIV-1 Gag and Env at the PM [13,18,19], even in endosomal HIV-1-containing compartments or multivesicular body (MVB)/late endosomes in macrophages [20,21]. In addition, after Gag accumulation at the budding site, CD81 and CD9 expression on the PM decreased [14] and were associated with released virions [18,22].

Regarding the therapeutic arsenal against HIV infection, peptide and protein candidates for HIV-1 therapy have been developed and HIV-1 replication can be successfully blocked by targeting Gag proteins, as reviewed previously [23]. However, naturally occurring Gag polymorphisms have been reported that can severely compromise the susceptibility of HIV-1 to the inhibitors. The CA protein was shown to contain the most conserved region in the Gag polyprotein [24]. Inhibitors targeting Gag have been improved over the years by identifying several new CA inhibitors. Small molecules or peptide inhibitors were designed to target many sites of CA, for instance, (i) small molecules targeting the N-terminal domain of HIV-1 CA (CA_{NTD}) such as CAP-1 [25], benzodiazepines [26], PF74 [27], and pyrrolopyrazolones [28]; (ii) small molecules and peptides targeting the C-terminal domain of HIV-1 CA (CA_{CTD}) such as CAI peptide [29], CAC-1 peptide [30], glycodeoxycholate [31], and ubselen [32]; and (iii) small molecules targeting CA-SP1, which is a less-conserved region in HIV-1 [33], such as bevirimat [34]. A maturation inhibitor was tested in a phase-II clinical trial, although testing was terminated because the inhibitor caused SP1 polymorphisms [35]. Viral variants resistant to the pyridone-based compound PF-46396, belonging to a second class of maturation inhibitors, were also reported [36]. Nevertheless, none of these inhibitors were reported to have a collateral effect on membrane remodelling.

Interestingly, a designed ankyrin repeat protein (DARPin), known as Ank^{GAG}1D4, was selected from phage-displayed ankyrin libraries based on its binding to HIV-1 CA_{NTD} [37], which is the most conserved region in HIV-1 CA [24]. The distinctive property of Ank^{GAG}1D4 is the ability to inhibit HIV-1 replication [37–39]. Viral production and loads decreased significantly in HIV-1-infected SupT1 cells stably expressing Ank^{GAG}1D4 or in culture supernatants, respectively [38]. Ank^{GAG}1D4 also inhibited HIV-1 replication in primary CD4+ cells [37]. Recently, molecular dynamics (MD) simulations and nanoparticle tracking analysis (NTA) elucidate the interaction between Ank^{GAG}1D4 and HIV-1 CA [40]. Despite
the in silico study supporting anti-HIV-1 activity of AnkGAG1D4, the molecular mechanisms whereby AnkGAG1D4 inhibits HIV-1 replication still remain undeciphered. In this study, we investigated the impact of AnkGAG1D4 on the late stages of viral replication: Gag polymerisation, RNA packaging, and CD81-based tetraspanin membrane remodelling. Our data indicated that AnkGAG1D4 disturbed Gag distribution in PM, resulting in reduced HIV production.

2. Materials and Methods

2.1. Cell Culture and Plasmids

HEK293T cells and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM of L-glutamine (Gibco, Waltham, MA, USA), 100 U/mL of penicillin (Gibco, Waltham, MA, USA), 100 mg/mL of streptomycin (Gibco, Waltham, MA, USA), and heat-inactivated fetal calf serum (10% v/v). Cells were cultured in humidified 5% CO2 atmosphere incubator at 37 °C.

The pCEP4 vector (Invitrogen, Waltham, MA, USA) for constitutively expressing N-terminus myristoylated (Myr (+)) ankyrin, including Myr (+) AnkGAG1D4 and non-binder Myr (+) AnkA2D3, was constructed and described previously [37]. Each ankyrin was fused with a green fluorescent protein (GFP) allowing the observation under fluorescent microscopy and analysis by flow cytometry.

A lentiviral vector CGW, a third-generation lentiviral vector, used as the backbone vector to transfer the genes for molecular scaffolds Myr (+) AnkGAG1D4 or Myr (+) AnkA2D3 into target cells, was constructed and described previously [39]. Tagging of enhanced-green fluorescent protein (EGFP) on C-terminus of ankyrin supported the detection of ankyrin expression inside the cells.

The pFC14K HaloTag® CMV Flexi vector (Promega, Madison, WI, USA) was used to produce a truncated, HIV-1 MA and CA (MACA) HaloTag® fusion protein. MACA was amplified from pNL4-3, obtained from the NIH AIDS Research and Reference Reagent Program (Division of AIDS, NIAID, NIH) and then cloned into the pFC14K HaloTag® vector, linearised with SgfI and EcoRI.

The pNL4-3MA-YFP-Δenv vector was used to generate pNL4-3MA-mCherry-Δenv [41]. Briefly, pNL4-3MA-YFP-Δenv was pretreated with ClaI to remove the yellow fluorescent protein gene, which was replaced with the ClaI-treated mCherry gene.

2.2. Production of VSV-G-Pseudotyped Lentivirus

VSV-G-pseudotyped lentiviral vector particles in this study were produced in HEK293T cells, using the calcium phosphate co-transfection method. To produce VSV-G-pseudotyped ankyrin-EGFP viral particles, HEK293T cells were seeded on 10-cm dishes (3.5 × 10^6 cells per dish), and co-transfected with the CGW transfer vector (10 µg/dish), the packaging construct pMDLg/pRRE (6.5 µg/dish), pRSV-Rev (2.5 µg/dish), and pMD.2G (3.5 µg/dish). Culture supernatant containing lentiviral vector particles were harvested at 24 and 48 h post-transfection, and concentrated by ultracentrifugation. The viral titers were determined by re-transduction of HEK293T cells with serial dilution of the samples and expressed as the percentage of EGFP positive cells determined by flow cytometry.

To produce VSV-G-pseudotyped HIV-1 Gag-mCherry virus particle. HEK293T cells were seeded on 10-cm dishes (6 × 10^6 cells per dish), and co-transfected with pNL4-3MA-mCherry-Δenv (7 µg/dish), pNL4-3Δenv (3.3 µg/dish), and pMD.2G (4.5 µg/dish) using the TransIT-X2 transfection reagent (Mirus Bio, Madison, WI, USA), according to the manufacturer’s protocol. The VSV-G-pseudotyped lentiviral particles were harvested from the culture supernatant collected at 48 h. Virions were filtered through sterile syringe filters with a 0.45 µm Millex-HA filter (Merck Millipore, Burlington, MA, US). The high-titer virions stocks were prepared by ultracentrifugation at 100,000 × g, at 4 °C, for 1.30 h. The viral pellets were resuspended in DMEM. The lentiviral titers were determined by transduction into HEK293T cells with serial dilution of the samples and expressed as the percentage of mCherry-positive cells determined by flow cytometer.
2.3. Establishment of HeLa Cells Stably Expressing Ankyrin

To generate HeLa cells stably expressing ankyrin, HeLa cells were transduced with the VSV-G-pseudotyped lentiviral vectors at MOI of 1 in a growth medium containing 8 µg/mL of Polybrene (Sigma Aldrich, Saint Louis, MO, USA). Each VSV-G-pseudotyped lentiviral vectors included VSVG–CGW–Myr (+) Ank\textsuperscript{GAG}1D4-EGFP, VSVG–CGW–Myr (+) Ank\textsuperscript{A3}2D3-EGFP. The transduced cells were then transferred to a humidified incubator, and maintained at 37 \(^{\circ}\)C and 5% CO\(_2\) for 24 h. The cells were washed three times with a fresh growth medium and further cultured in fresh growth medium. The efficiency and stability of transduction were determined by fluorescence microscope and flow cytometer.

2.4. Analysis of Gag Distribution on the PM

To determine the distribution of Gag on the PM, HeLa cell monolayers (approximately 1 \(\times\) 10\(^5\) cells/well in 24-well plates) were transfected with 1µg of plasmid, including pCEP4 plasmid carrying ankyrin-encoding gene (i.e., pCEP4-Myr (+) Ank\textsuperscript{GAG}1D4-GFP, pCEP4-Myr (+) Ank\textsuperscript{A3}2D3-GFP) and/or pFC14K-MACA HaloTag\textsuperscript{®}, using the transIT-X2 transfection reagent (Mirus Bio, Madison, WI, USA). The cells were grown in humidified 5% CO\(_2\) atmosphere incubator at 37 \(^{\circ}\)C for 48 h. MACA HaloTag\textsuperscript{®}-expressing cells were stained with the HaloTag\textsuperscript{®} TMR Direct\textsuperscript{™} ligand (Promega, Madison, WI, USA) at a 1:1000 dilution for 16 h humidified 5% CO\(_2\) atmosphere incubator at 37 \(^{\circ}\)C. The cells were then fixed with 4% paraformaldehyde and mounted using ProLong\textsuperscript{™} Diamond Antifade Mountant with DAPI (Thermo Scientific, Waltham, MA, USA). The fixed cells were viewed using a Leica TCS SP8 stimulated emission-depletion (STED) microscope. Raw images were iteratively deconvolved with Huygens software (Scientific Volume Imaging, Hilversum, The Netherlands).

2.5. Investigation of RNA Packaging and Gag Production

Transfection: 5 \(\times\) 10\(^6\) cells (HEK293T cells) were seeded into wells and allowed to attach overnight. Two micrograms of pNL4-3\(\Delta\)env along with carrier DNA (pSP72 plasmid) or 1.6 µg (pNL4-3\(\Delta\)env) with or without pCEP4-(Myr+) Ankyrin-GFP (0.5:1 or 1:1 molar ratio with pNL4-3\(\Delta\)env) were co-transfected into HEK293T cell monolayers using the Lipofectamine\textsuperscript{™} 3000 Transfection Reagent (Thermo Scientific, Waltham, MA, USA), according to the manufacturer’s recommended procedure. Virion-containing supernatants were collected at 24 h post-transfection, centrifuged at 100,000 \(\times\) g for 1.30 h at 4 \(^{\circ}\)C. The pellets were resuspended in 160 µL of DMEM. Next, 25 µL of each virion sample was used for protein analysis, 125 µL was used for RNA extraction, and 10 µL was used for p24 quantification using a modified Genscreen\textsuperscript{TM} ULTRA HIV Ag-Ab Assay (Bio-Rad, Hercules, CA, USA).

RNA extraction: RNA from concentrated virus samples was extracted using the QIAamp Viral RNA Mini Kit in the presence of 5.6 µg of carrier RNA (Poly A) according to manufacturer’s recommended procedure (Qiagen, Hilden, Germany). The viral RNAs were then treated with DNase I (Thermo Scientific, Waltham, MA, USA) to eliminate the remaining DNA. Then, dried pellets containing 3 \(\times\) 10\(^6\) cells were used for total cellular RNA extraction with a High Pure RNA Isolation Kit (Roche, Basel, Switzerland) in the presence of DNase, according to manufacturer’s recommended procedure.

Protein analysis: The remaining dried cell pellets were lysed to extract cellular protein using RIPA Lysis and Extraction Buffer (Thermo Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. Total protein was measured using the Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Proteins in 100 µg of cell lysate or 25 µL of concentrated virion were separated using SDS-PAGE and transferred to nitro-
cellulose membrane. HIV-1 Gag was detected with a mouse anti-CA antibody (hybridoma H183, NIH AIDS Reagent Program). Ankyrin protein expression was determined with a GFP Monoclonal Antibody. Horseradish peroxidase-conjugated (HRP) anti-mouse IgG (Seracare, Milford, MA, USA) was used as a secondary antibody. Cellular actin was detected using an HRP-conjugated mouse monoclonal anti-β-actin antibody (clone AC-15, Sigma-Aldrich, Saint Louis, MO, USA). ECL fluorescence was recorded using a ChemiDoc™ Touch Imaging System (Bio-Rad, Hercules, CA, USA).

Quantification of p24 in concentrated virions by performing p24 ELISA: The Genscreen™ ULTRA HIV Ag-Ab Assay Kit (Bio-Rad, Hercules, CA, USA) was modified by replacing conjugate 1 with a biotinylated anti-capsid (CA) antibody and pre-incubating the sample with 10% Triton X-100 (virion lysis buffer, Thermo Scientific, Waltham, MA, USA) at 37 °C for 30 min before beginning the manufacturer’s protocol.

RNA quantification: Reverse transcription (RT) was performed using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche, Basel, Switzerland) with 1 µg of total cellular RNA sample or 0.5 µg of virion RNA. An oligo (dT) primer was used as an RT primer for viral RNAs and GAPDH mRNA, whereas specific internal primers were required for RT of 7SL and U6 RNA. After the RT reactions, the RT products were diluted, and quantitative polymerase chain reaction (PCR) experiments were run on a CFX96 Real-Time System (Bio-Rad, Basel, Switzerland). The RT products were amplified with 40 cycles of PCR: 95 °C for 15 s, 58 °C for 12 s, and 72 °C for 20 s. The pair of primers (Table 1) were used at the final concentration of 0.5 mM in the real-time PCR for FL HIV-1 RNA, MS HIV-1 RNA, HIV-1 env RNA, GAPDH, 7SL, and U6. Quantification was performed using a standard curve comprised of 10² to 10⁹ copies of the pNL4-3 plasmid.

Table 1. List of primer used in RT-qPCR.

| Target RNA   | Primer Name | Primer Sequence               |
|--------------|-------------|-------------------------------|
| FL HIV-1 RNA | sHIV-1306   | 5'-TCAGCATTATCAGAAGGAGGCCACC-3' |
|              | aHIV-1541   | 5'-TCATCCATCCTATTTGTCTCTGAAG-3' |
| MS HIV-1 RNA | sHIV-5967   | 5'-CTATGGCAGGAGAACGGGAG-3'  |
|              | aHIV-8527   | 5'-CAAGCGTTGGAAGCTGAAAGG-3'  |
| HIV-1 env RNA| sHIV-729SD1A5 | 5'-GAGGGCGCGCGACTGGAAGAA-5' |
|              | aHIV-6134   | 5'-ACTATGGACACAAACTATTGC-5'  |
|              |             | 5'-GCACCCTTGCGATGCTCCCGG-5'  |
|              |             | 5'-GGAGGAGTGGGTTGCGCTGTTGA-5' |
| GAPDH        | GA-721      | 5'-GCTCACCACGATGCTCCCGGT-5'  |
|              | GA-931      | 5'-CTGTAGCTCCAGCTAATCCG-5'   |
| 7SL          | s7S-22      | 5'-CTGTAGCTCCAGCTAATCCG-5'   |
|              | a7S-148     | 5'-GCCGAAGTGGTGTCCGCTGTTGA-5' |
| U6           | sU6-3       | 5'-GCTCGCTCGCGCGAGCAATATCT-5' |
|              | aU6-103     | 5'-TATGGAAGCCTCCAGGAATTGCG-5' |

2.6. Determination of an Effect of AnkGAG1D4 on HIV-1 Protease Activity

An effect of ankyrin on HIV-1 protease activity was determined using ELISA. The microtiter plate was coated with 5 µg/mL of recombinant H₆MA-CA (His6-Matrix-Capsid) and incubated at 4 °C for 16 h. Then, the coated plate was washed with washing buffer 1 (0.05% Tween-20 in PBS) and blocked with 2% skim milk-PBS for 1 h. Next, plate was washed with washing buffer 1. The 5 µg/mL of recombinant AnkGAG1D4 or AnkA2D3 (irrelevant ankyrin repeat protein) diluted in binding buffer (2% of BSA in 0.05% Tween 20-PBS) were added to coated well, then the reaction was placed at room temperature for 1 h. The H₆MA-CA-binding activity of ankyrin was detected by rabbit anti-ankyrin polyclonal antibody (pre-absorbed with 5% of BSA in 0.05% Tween 20-PBS for 1 h) followed by goat anti-rabbit immunoglobulins-HRP (diluted in binding buffer). Besides, after 1 h incubation of Ankyrin to H₆MA-CA coated plate, the HIV-1 protease activity was performed, the non-specific binding was washed with washing buffer 2 (1% Triton X100 (v/v) and 550 mM NaCl prepared in PBS, pH 7.4). The 6 mg/mL of soluble HIV-PR (diluted in binding buffer),
while bacterial lysate BL21(D3) was used as a control, was added to the wells, and the plate was incubated at 37 °C for 1 h. Then, the wells were washed with washing buffer 2. The presence of the free C-terminus of MA after cleaving by HIV-PR was detected by an anti-MA (HB-8975) monoclonal antibody (specifically binds to the free C terminus of cleaved HIV-MA) followed by a goat anti-mouse immunoglobulins-HRP (diluted in binding buffer). The wells were then washed; followed by TMB substrate being added. The wells were then washed again with washing buffer 2 prior to adding SureBlue™ TMB Microwell Substrate (KPL) and the optical density at 450 nm (OD 450 nm) were measured after adding 1 N HCl.

2.7. Investigation of the Influence of Ank\textsuperscript{GAG}1D4 on Organisation of CD81 during HIV-1 Assembly

HeLa cells or HeLa cells stably expressing ankyrin were transduced with VSV-G-pseudotyped HIV-1 Gag-mCherry at MOI of 2 in a growth medium containing 8 µg/mL of Polybrene (Sigma-Aldrich, MO, USA). Transduced HeLa cells were incubated in humidified 5% CO\textsubscript{2} incubator. The excess lentiviruses were washed after 1 day of transduction. On the next following day, cells were collected to be analysed for CD81 expression using direct immunofluorescence staining and flow cytometry.

The direct immunofluorescence staining was performed in the adhered transduced HeLa cells on coverslip. Cells were washed with PBS and fixed with 4% paraformaldehyde-PBS for 10 mins at room temperature. Cells were then washed twice with PBS and blocked with 10% human AB serum-PBS. Next, cells were stained with 100 µg/mL of Pacific Blue™ anti-human CD81 (Biolegend, San Diego, CA, USA). Finally, cells were washed and mounted with ProLong™ Gold Antifade Mountant (Thermo Scientific, Waltham, MA, USA). The CD81, Gag-mCherry, and Ankyrin-EGFP were visualised under a Nikon C2 plus confocal microscope. Excitation wavelengths were 405 nm for Pacific Blue, 488 nm for EGFP, and 560 nm for mCherry.

The transduced HeLa cells were also performed flow cytometry analysis to determine the surface CD81 expression by staining with 100 µg/mL of Pacific Blue™ anti-human CD81 (Biolegend, San Diego, CA, USA).

2.8. Statistical Analysis

Results are presented as the mean ± standard deviation (SD) of three independent assays. Statistical comparisons were determined by one-way analysis of variance (ANOVA) with GraphPad Prism software. Statistically significance was indicated as asterisk (*** p < 0.001; ** p < 0.01; * p < 0.1; ns, not significant).

3. Results

3.1. Ank\textsuperscript{GAG}1D4 Affected Gag Production in HIV-1-Producer Cells

HEK293T cells were co-transfected with pNL4-3\textsuperscript{△env} plasmid with or without pCep4-Myr (+) Ank\textsuperscript{GAG}1D4-GFP or pCep4-Myr (+) Ank\textsuperscript{A3}2D3-GFP (1:1 molar ratio with pNL4-3\textsuperscript{△env}). Proteins were extracted from cell pellets and concentrated virus samples, and analysed by western blotting with antibodies against CA, GFP, and β-actin. The results show that both Ank\textsuperscript{GAG}1D4 and Ank\textsuperscript{A3}2D3 (non-binder ankyrin control) were expressed in transfected cells as detected based on GFP expression but were not incorporated into virions (Figure 1A). The presence of both Ank\textsuperscript{GAG}1D4 and Ank\textsuperscript{A3}2D3 did not interfere with the Gag-processing pattern as Pr55Gag was processed to the p41 and p24 CA proteins. The accumulation of Pr55Gag and the p41 CA precursor was observed inside HEK293T cells transfected with the pNL4-3\textsuperscript{△env} and pCep4-Myr (+) Ank\textsuperscript{GAG}1D4-GFP (Figure 1B). In contrast, in the presence of (Myr (+)) Ank\textsuperscript{GAG}1D4, little or no virion release was observed, as shown by the strong decrease of p24 intensity in viral lysate (Figure 1A, B). Additionally, HIV-1 Gag processing efficiency from viral lysate was determined using image lab software (Figure 1C). The gag processing efficiency in the presence of (Myr+) Ank\textsuperscript{GAG}1D4 was lower than the control cells. This evidence associates with the reduction in virion release. These
results indicated that the intracellular expression of Ank\textsuperscript{GAG}1D4 impaired virion release; thus, Gag accumulated inside the cells without affecting the Gag processing.

Figure 1. The effect of Ank\textsuperscript{GAG}1D4 on Gag polyprotein levels inside Gag-producing cells and virions. (A) Representative western blot images of Gag in cells and virions released from HEK293T cell after 24 h co-transfected with an HIV-1 Δenv construct, with or without pCEP4-Myr (+) Ank\textsuperscript{GAG}1D4-GFP or pCEP4-Myr (+) Ank\textsuperscript{A3}2D3-GFP. Gag was detected using a mouse anti-CA antibody, and the expression of designed ankyrin repeat proteins was detected with an anti-GFP antibody. (B) A band-intensity histogram related to Gag proteins in cells was generated with Image lab software, and represented in a bar graph showing the relative intensity of Gag proteins normalised to HIV Δenv alone. (C) The percentage of HIV-1 Gag processing efficiency was calculated from the band intensity of HIV-1 Pr55, p41, and p24 in viral lysate using the p24/(pr55 + p41 + p24) formula. HEK293T cells transfected with pNL4-3 Δenv were used to normalise the data. Data represent the mean ± SD from the triplicate independent assay. *** p < 0.001; ns, not significant using one-way ANOVA.

3.2. Ank\textsuperscript{GAG}1D4 Is Not Associated with HIV-1 Protease Cleavage Site

According to Figure 1A, a few amounts of virion release and accumulation of Pr55Gag and the p41CA precursor inside the Gag-producing cells were observed, in the presence of Ank\textsuperscript{GAG}1D4 as shown in Figure 1A. To confirm whether the binding of Ank\textsuperscript{GAG}1D4 with HIV-1 capsid does not reside in the protease cleavage sites, Gag polyprotein processing by HIV-1 protease was determined using enzyme-linked immunosorbent assay (ELISA). In this experiment, the H\textsubscript{6}MA-CA recombinant protein, which contains the HIV-1 protease cleavage site between MA and CA, was used as a model. First, the specific binding of Ank\textsuperscript{GAG}1D4 with coated H\textsubscript{6}MA-CA was determined. The result demonstrated the specific interaction of Ank\textsuperscript{GAG}1D4 with coated H\textsubscript{6}MA-CA compared to Ank\textsuperscript{A3}2D3 (Figure 2A).

Next, in order to exhibit that Ank\textsuperscript{GAG}1D4 did not interfere with the HIV-1 protease cleavage site, Ank\textsuperscript{GAG}1D4 was prior incubated with coated H\textsubscript{6}MA-CA for 1 h to ensure that the binding of Ank\textsuperscript{GAG}1D4 with its target was achieved. Then, the HIV-1 protease was added to the bound H\textsubscript{6}MA-CA. The protease activity was measured by the presence of a free C-terminus of HIV-MA after cleaving with HIV-1 protease. The result confirmed that the binding of Ank\textsuperscript{GAG}1D4 with H\textsubscript{6}MA-CA did not interfere with the HIV-1 protease cleavage site as detected by free C-terminus of HIV-MA after cleaving with HIV-1 protease at the same levels as Ank\textsuperscript{A3}2D3 and control (Figure 2B).

3.3. Ank\textsuperscript{GAG}1D4 Impaired Gag Distribution at the PM

As viral release was impaired by Ank\textsuperscript{GAG}1D4, we were interested in determining which steps of virus assembly were affected. In this experiment, HIV-1 Gag distribution in
Figure 2. The effect of AnkGAG1D4 on HIV-1 protease activity. ELISA was performed to determine the effect of ankyrin protein on HIV-1 Gag processing by Protease. (A) The H6-MA-CA-binding activity of artificial ankyrins. Plate was coated with recombinant H6-MA-CA. Next, AnkGAG1D4 (Black bar) or AnkA32D3 (Gray bar) was added to H6-MA-CA coated well and incubate for 1 h. The H6-MA-CA-binding activity was detected by adding rabbit anti-ankyrin polyclonal antibody followed by goat anti-rabbit immunoglobulins-HRP. The data presented in the bar graph was formerly normalised with no ankyrin control. (B) The activity of HIV-1 protease was determined using ELISA. Plate was coated with the target of HIV-1 protease (recombinant H6-MA-CA). Prior to adding HIV-1 protease, the coated plate was incubated with BSA (White bar), AnkGAG1D4 (Black bar), or AnkA32D3 (non-binding ankyrin protein) (Gray bar) for 1 h. The protease activity was determined by the presence of free C terminus of cleaved HIV-MA after cleaving with HIV-1 protease. The detection was measured by adding an anti-MA (HB-8975) monoclonal antibody (binds to the free C terminus of cleaved HIV-MA) followed by a goat anti-mouse immunoglobulins-HRP. The results represent as mean ± SD from a triplicate independent assay. *** p < 0.001; ns, not significant using one-way ANOVA.

3.4. AnkGAG1D4 Affected RNA Packaging

HIV-1 Gag specifically recognises the FL RNA dimer in the cytosol and traffics to the PM as a Gag–FL RNA complex to join Gag-containing particles and displace RNA-containing particles at assembly sites [4]. Additionally, other viral RNAs (MS, env) and cellular RNAs can be packaged into the virion. Since AnkGAG1D4 modifies the Gag pattern at the PM, we tested whether AnkGAG1D4 could also affect FL RNA packaging into new viral particles. To do so, HEK293T cells were co-transfected with pNL4-3Δenv and pCEP4-Myr (+) Ankyrin (AnkGAG1D4 or AnkA32D3)-GFP (0.5:1 molar ratio with pNL4-3Δenv). After 24 h post-transfection, cells and virions were collected, then subjected to RNA extraction. RNA samples were studied by RT-qPCR analysis of viral (FL, MS, and env) and cellular (GAPDH, 7SL, and U6) RNAs. The result indicates that AnkA32D3 and AnkA32D3 did not affect the levels of viral and cellular RNAs in transfected cells.
The molar ratio of pNL4-3Δenv to pCEP4-Myr (+) Ankyrin at 1:1 was not appropriate since the amount of generated virion was not sufficient for further analysis (Figure 1A). We diminished the inhibitory effect of AnkGAG1D4 in HIV-1 transfected cells, the molar ratio of pNL4-3Δenv to pCEP4-Myr (+) Ankyrin was adjusted to 2:1 for sufficient virions collected to analyse their RNA contents by RT-qPCR. The results showed that both AnkGAG1D4 and AnkA32D3 decreased the intravirion levels of viral RNAs (FL, MS, and env) and cellular RNAs (U6 small nuclear RNA (snRNA) and 7SL), compared to HEK293T cells expressing HIV-1Δenv alone (Figure 4B). AnkGAG1D4 reduced the intravirion viral and cellular RNA levels much more than AnkA32D3 (except for 7SL RNA; Figure 4B).

**Figure 3.** Co-expression of Ankyrin-GFP proteins and the MACA-HaloTag® protein in HeLa cells. Gag distribution at the membrane of HeLa cells expressing ankyrin was visualised by STED microscope. (A) HeLa cells were transfected with pFC14K-MACA-HaloTag® alone, (B) co-transfected with pCep4-Myr (+) AnkGAG1D4-GFP and pFC14K-MACA HaloTag®, or (C) co-transfected with pCep4-Myr (+) AnkA32D3-GFP and pFC14K-MACA HaloTag®. After 48 h incubation, cells were stained with the HaloTag® TMR Direct™ ligand, then mounted with ProLong™ Diamond Antifade Mountant with DAPI. The white squares indicate areas of interest in the PM of HeLa cells that are shown at higher zoom levels. The data shown in this figure is a representative of several imaged fields. Green represents GFP-tagged ankyrin expression in HeLa cells. Blue is the nucleus, and red indicates MACA- HaloTag® protein.

Additionally, viral release was measured by p24 ELISA. A control experiment was systematically performed without 10% Triton X-100 to control for the absence of cellular p24 contamination. As shown in Figure 4C, AnkGAG1D4 decreased the production of viral progeny, even though it was not totally abolished because we adjusted the inhibitory effect of AnkGAG1D4, as described above. Notably, without 10% Triton X-100, the p24 levels in all samples were undetectable, indicating that the p24 levels measured corresponded to intravirion p24. An equal number of viral particles (100 ng of p24) was subjected to compensate for the level of VLP-associated Gag. The level of differential RNA contents from the same number of virions was analysed. Both ankyrins negatively reduced the viral RNA contents (Figure 4D) and affected the packaging of both viral RNAs and cellular RNAs
Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.

(Figure 4E). Interestingly, in comparison to Ank\textsuperscript{A3}D3, Ank\textsuperscript{GAG}1D4 drastically decreased RNA packaging (Figure 4E). Especially for the incorporation of FL HIV-1 RNA, which reflected the indispensable for infectious virion. However, Ank\textsuperscript{GAG}1D4 promoted significantly higher incorporation of 7SL cellular RNA into viral particles than did Ank\textsuperscript{A3}D3. This result indicated that viral particles released from the Ank\textsuperscript{GAG}1D4-Gag producing cells lost their potential to encapsidate viral RNAs and cellular RNAs.
3.5. Ank\textsuperscript{GAG1D4} Restored CD81 Tetraspanin Localisation at the PM in Gag-Expressing Cells

During HIV-1 assembly and release, the tetraspanins transmembrane glycoprotein form dynamic networks with other proteins and HIV-1 proteins including HIV-1 Gag and Env at the PM [13,18,19]. Additionally, CD81 and CD9 tetraspanins expression on the PM were found to decrease during viral release [14] and were incorporated with released virions [18,22]. For this reason, we hypothesised that the distortion of Gag polymerisation by Ank\textsuperscript{GAG1D4} could affect the CD81 tetraspanin remodelling at the PM. To address this issue, CD81 tetraspanins remodelling was assessed using conventional confocal microscopy. In this experiment, HeLa cells and ankyrin-expressing HeLa cells were transduced with VSV-G pseudotyped HIV-1 GagmCherry. At 48 h post-transduction, immunostaining was performed to demonstrate the distribution of CD81 tetraspanins under confocal microscopy. In this experiment, as Ank\textsuperscript{GAG1D4} influenced the HIV-1 Gag distribution at the PM (Figure 3C), tetraspanin recruitment to virus-assembly sites was considered. CD81 tetraspanin distribution in the PM of HeLa and ankyrin expressing HeLa cells was initially determined using confocal microscopy. Regarding confocal imaging, surface expression of CD81 remained with Myr (+) Ank\textsuperscript{GAG1D4-EGFP} or Myr (+) Ank\textsuperscript{A32D3-EGFP} expressing HeLa cells (Figure 5C,E, respectively).

Additionally, the level of overall surface CD81 expression in ankyrin-expressing cells was confirmed by flow cytometry. Accordingly, high expression levels of Ankyrin protein did not disturb the expression of CD81 at the PM (Figure 6B). Therefore, the high-expressing Ankyrin protein was used in further study. Next, we analysed the surface expression of CD81 on HeLa cells expressing Gag-mCherry. Most of the HeLa transduced cells were positively expressed Gag-mCherry and were defined in 2 populations: cells with intermediate (mCherry+) and high (mCherry++) levels of Gag-mCherry expression (Figure 6A). After staining with anti-human CD81, the surface CD81 expression disappeared on PM of HeLa cells expressing Gag-mCherry (Figure 5B) and the CD81 intensity was decreased by 50% in cells strongly expressing Gag-mCherry as compared to the non-transduced cells (Figure 6C). This result agreed with another study showing that CD9 and CD81 tetraspanin levels decreased in the PM at 48 h post-transfection in HeLa cells expressing Gag-GFP (14). Surprisingly, introducing HIV-1 Gag-mCherry into HeLa cells strongly expressing Ank\textsuperscript{GAG1D4} cells efficiently maintained the CD81 tetraspanin on the PM up to 95% in the intermediate expression of Gag-mCherry and 86% in the high expression of Gag-mCherry (Figure 6C). Nevertheless, the 80% (in the intermediate expression of Gag-mCherry) and 70% (in the high expression of Gag-mCherry) surface CD81 restoration were observed in HIV-1 Gag-mCherry transduced HeLa cells stably expressing Ank\textsuperscript{A32D3} (Figure 6C). This phenomenon reflects the effect of the N-terminus myristoyl group of AnkA32D3 inserted into the inner leaflet of the cell membrane leading to nonspecifically disturbing of HIV-1 Gag assembly. Comparing the efficient restoration of surface CD81 between Ank\textsuperscript{GAG1D4} and Ank\textsuperscript{A32D3} in HIV-1 Gag-mCherry transduced cells, the Ank\textsuperscript{GAG1D4} was significantly sustained the CD81 distribution at the PM in both cells with intermediate ($p < 0.001$) and high ($p < 0.001$) levels of Gag-mCherry expression than Ank\textsuperscript{A32D3}. These findings indicated that disturbing Gag distribution at PM by Ank\textsuperscript{GAG1D4} impaired membrane remodelling during virus egress.
Figure 5. CD81 tetraspanin organisation at the PM during HIV-1 release. HeLa or HeLa cells stably expressing ankyrin (EGFP) were transduced with VSV-G-pseudotyped HIV-1 GagmCherry. After 48 h, cells were harvested, and stained with Pacific Blue™ anti-human CD81. CD81 tetraspanin organisation was visualised under conventional confocal microscopy. (A) Non-transduced HeLa cells, (B) Transduced HeLa cells, (C) HeLa cells stably expressing Myr (+) AnkA32D3, (D) Transduced HeLa cells stably expressing Myr (+) AnkA32D3, (E) HeLa cells stably expressing Myr (+) AnkGAG1D4, (F) and transduced HeLa cells stably expressing Myr (+) AnkGAG1D4. Scale bar: 10 µm. The image shown in this figure is a representative data of several imaged fields. Blue, green and red represent CD81 tetraspanin, EGFP-tagged ankyrin, and GagmCherry, respectively.
Figure 6. CD81 tetraspanin surface intensity and viral production. HeLa cells and HeLa cells stably expressing Myr (+) Ank<sup>GAG</sup>1D4-GFP or Myr (+) Ank<sup>A3D3</sup>-GFP were transduced with VSV-G-pseudotyped HIV-1 GagmCherry. (A) After 48 h, the level of ankyrin expression and HIV-1 GagmCherry expression was analysed by flow cytometry. Populations were defined based on their fluorescence intensity ((+) = intermediate expression, (++) = high expression). (B) Surface CD81 expression on non-transduced cells was measured by flow cytometry. The intensity of CD81 on non-transduced HeLa and ankyrin-expressing HeLa cells was shown in Bar graph. (C) Surface CD81 expression on transduced HeLa and ankyrin-expressing HeLa cells was determined by flow cytometry. Relative surface CD81 intensity was calculated by the percentage of surface CD81 intensity of transduced cells and normalised against surface CD81 intensity of non-transduced cells. Data represent the mean ± SD from triplicate independent assay. Significant differences (***, *p* < 0.001; ns, not significant) were determined between transduced and non-transduced HeLa cells or ankyrin-expressing HeLa cells using one-way ANOVA. Ank<sup>GAG</sup>1D4, Ank<sup>A3D3</sup> represent HeLa cells stably expressing Myr (+) Ank<sup>GAG</sup>1D4-EGFP and Myr (+) Ank<sup>A3D3</sup>-EGFP, respectively.

4. Discussion

Ank<sup>GAG</sup>1D4 is a designed ankyrin repeat that binds a conserved sequence in the N-terminal region of the HIV-1 CA protein. Ank<sup>GAG</sup>1D4 exhibits intracellular antiviral activity in the viral assembly process [37,38]. Recently, Ank<sup>GAG</sup>1D4 exerts broad-spectrum antiviral activity by blocking the assembly of chimeric NL4-3-based virions derived from circulating strains among northern Thai patients [39]. Additionally, an affinity-improved Ank<sup>GAG</sup>1D4 successfully demonstrated the enhancement of anti-HIV-1 activity in HIV-1 NL4-3 and HIV-1 maturation inhibitor-resistant (MIR) virus [42]. Although Ank<sup>GAG</sup>1D4 performs a potent anti-HIV activity in HIV-1 infected cells, more understanding of molecular mechanisms which impaired HIV-1 production is required.

In this study, we showed that Ank<sup>GAG</sup>1D4 did not interfere with the protease cleavage site, since the accumulation of the Pr55 Gag precursor and p41 proteins was observed inside the cells. Moreover, the CA p24 protein (the final product of Gag maturation) was detected in relatively few viral particles released from cells expressing Ank<sup>GAG</sup>1D4. Moreover, this
phenomenon was confirmed by directly detecting the free C-terminus epitope of cleaved HIV-MA generated by HIV-1 protease-cleaved H6MACA. This epitope was specifically captured by monoclonal antibody HB-8975 [43]. This data indicated that the interaction of Ank\(^{GAG}\)1D4 to HIV-1 CA did not hinder or alter the HIV-1 protease cleavage site on recombinant H6MACA.

The late stages of the HIV-1 life cycle include many events (such as intracellular trafficking, assembly, budding, release, and maturation) in which Gag plays a key role. Disturbing these processes diminishes the production of HIV-1 infectious particles. Inside Gag-producing cells, PI (4,5) P2 phospholipids interact with the HBR of MA and allosterically promote the release of sequestered myristate into lipid bilayers (2,3). The cytosolic, compact shape of Gag can be converted to an extended form and form polymers with other Gag proteins in the extended form [44]. Previously, using conventional pinhole confocal microscopy, the specific colocalisation of Myr (+) Ank\(^{GAG}\)1D4 and HIV-1 Gag at the PM of infected cells was observed [38]. Unexpectedly, Gag colocalisation with Myr (+) Ank\(^{A3}\)2D3, which does not bind to HIV-1 Gag, was also observed. Due to the diffraction limit of the light used for conventional confocal microscopy, it is not possible to distinguish spots less than 200 nm apart [45]. Thus, in this study, STED was used to overcome this limitation and monitor Gag distribution pattern at the PM. Previously, STED was employed to visualise the distribution of the Env glycoprotein on the surface of HIV-1 particles [46]. In addition, STED was recently used to demonstrate that HIV-1 Gag specifically restricts PI (4,5) P2 and cholesterol at assembly sites [47]. Using STED microscopy, we clearly observed that the MACA-HaloTag\(^{®}\) distributed continuously at the PM of MACA-HaloTag\(^{®}\) expressing cells. However, the continual pattern of MACA-HaloTag\(^{®}\) was clearly impaired in the presence of Ank\(^{GAG}\)1D4 (Figure 3C). The apparent visualisation of dark gaps on the cell surface implied that embedding of Ank\(^{GAG}\)1D4 in the PM probably influenced the Gag polymerisation (Figure 3C). To prove this, the electron microscopic (EM) analysis should be applied to assure the disturbance of MACA-HaloTag\(^{®}\) at the plasma membrane resulting in the disruption of CA lattice formation in defective viral progeny. Noticeably, the efficiency of HIV assembly was disrupted resulting in the reduction of viral progeny. Even though Ank\(^{GAG}\)1D4 efficiently reduces viral production, the effects of Ank\(^{GAG}\)1D4 on viral budding and membrane scission through the ESCRT machinery should be further investigated. ESCRT is not only associated with viral budding, but also participates in MVB biogenesis, which is important for transporting ubiquitinated protein for degradation [48]. As shown in Figure 3B, Myr + Ank\(^{A3}\)2D3 mainly localised in the cytoplasm. We inferred the involvement of the ESCRT degradation pathway, since Gag was not the specific target of Myr + Ank\(^{A3}\)2D3. Furthermore, the indirect disturbance of Gag-Gag multimersation by maturation inhibitor, bevirimat, caused abnormal virion morphology [49]. Likewise, the aberrant virion morphology caused by other CA, assembly, or maturation inhibitors has been well characterized and described by using electron microscopy [50–52]. Altering this critical step of HIV assembly by Ank\(^{GAG}\)1D4 possibly causes aberrant virion production. Investigation of the alteration of virion morphology produced by Ank\(^{GAG}\)1D4 expressing cells using EM should be further evaluated.

Because Ank\(^{GAG}\)1D4 did not significantly disturb the cellular FL HIV-1 RNA level, an effect on HIV-1 RNA transcription was excluded. Therefore, accumulation of the Gag polyprotein inside Ank\(^{GAG}\)1D4 expressing cells resulted from the retardation of the Gag polyprotein-release rate during the assembly process. As the extended Gag conformation generally uses the NC domain to recruit FL RNA and initiate the viral-assembly stage [53]. RNA levels in virions and RNA-packaging efficiency have been studied by RT-qPCR (reviewed in [54]). In this study, Gag clearly lost its ability to specifically incorporate FL HIV-1 RNA into virions in the presence of Ank\(^{GAG}\)1D4 (Figure 4D,E). The ability of Gag to multimerize on RNA via the NC domain is important for RNA packaging. Since NC is not the target of Ank\(^{GAG}\)1D4, the mechanism of Ank\(^{GAG}\)1D4 should rather participate in the disturbance of Gag multimerisation. The networking of Gag is crucial for successfully stabilizing RNA at the plasma membrane in the preassembly stage [53,55]. According to
STED analysis, the impairment of Gag distribution in Ank\textsuperscript{GAG1D4} expressing cells was indicated, thus, reflecting the interference of the Gag polymerisation process. In general, FL HIV-1 RNA and spliced RNA can be packaged into virions due to the presence of an internal loop and the lower part of SL1 in the 5′-untranslated region of HIV-1 RNA. However, FL HIV-1 RNA is preferably selected by the Gag precursor with higher affinity than spliced RNA due to the counterbalance-regulation domain spanning nucleotides downstream of SL4 and upstream of SL1, and the specific region between nucleotides 355–400, which is not present in spliced RNA [8,10]. Accordingly, the presence of Ank\textsuperscript{GAG1D4} also interfered with the incorporation of spliced RNAs (MS and env RNA) and cellular RNAs (U6 snRNA and 7SL) into nascent virions. Data from several studies showed that HIV-1 particles can specifically package small Pol-III transcripts in addition to FL RNA [11]. Ank\textsuperscript{GAG1D4}-Gag expressing cells not only lost HIV-1 RNA encapsidation, but also cellular RNA incorporation (Figure 4D,E). Compared to Ank\textsuperscript{A32D3}, the FL RNA reduction induced by Ank\textsuperscript{GAG1D4} was accompanied by increased 7SL RNA incorporation into virions (Figure 4D,E). Interestingly, these opposing effects on the FL and 7SL RNA packaging levels were also reported when the packaging signal was deleted from FL RNA [9]. Additionally, increasing 7SL RNA incorporation in virions was possibly caused by Gag accumulation induced by Ank\textsuperscript{GAG1D4}, since Gag accumulation inside producer cells previously promoted 7SL RNA incorporation into virions [56]. A partial reduction of the RNA-packaging efficiency was also observed in the presence of Ank\textsuperscript{A32D3}, which may have been caused by competition between the myristoyl group of Ank\textsuperscript{A32D3} and Gag in recruiting cholesterol molecules [57]. In contrast to Ank\textsuperscript{A32D3}, a tremendously impaired RNA packaging in Ank\textsuperscript{GAG1D4} expressing cells was significantly observed. Additionally, it was clear that the alignment of Gag at PM in Ank\textsuperscript{A32D3}-Gag-expressing cells was not disturbed (Figure 3B), as Gag is not the specific target of Ank\textsuperscript{A32D3}. Thus, RNA incorporation partially occurred in the presence of Ank\textsuperscript{A32D3}.

The clustering of tetraspanins with Gag and Env at the PM has been observed in diverse types of HIV-1 infected cells [18,58]. Gag polymerisation at the PM can induce the formation of microdomains, including TEMs [59]. TEMs have been proposed as gateways for HIV-1 assembly and budding [14,60]. We observed that at 48 h post-transduction with VSV-G-pseudotyped HIV-1 GagmCherry, the CD81 tetraspanin vanished from the PM. Diminishing PM expression of the CD81 tetraspanin in HIV-1-infected cells was related to VLP release [14]. Interestingly, we also observed that inhibiting HIV-1 egress with Ank\textsuperscript{GAG1D4} caused a rebound of CD81 tetraspanin on the PM of HIV-1 Gag-expressing cells. These data indicated that Ank\textsuperscript{GAG1D4} caused membrane remodelling during viral release, since Gag polymerisation was disturbed. Beyond Ank\textsuperscript{GAG1D4}, no other small molecules or peptide inhibitors targeting CA have been reported to affect the remodelling of tetraspanins on the PM. Moreover, the presence of tetraspanins at exit sites can reduce syncytial formation in virus-producing cells and cell-to-cell fusion induced by the virus [61,62]. Because Ank\textsuperscript{GAG1D4} is capable of preventing syncytial formation [37–39], it is worth further investigating its utility in blocking viral transfer via cell-to-cell contact.

5. Conclusions

The data obtained in this study illustrate the molecular mechanisms whereby Ank\textsuperscript{GAG1D4} blocks HIV replication. The intracellular expression of Ank\textsuperscript{GAG1D4} disrupted the primary checkpoint at the late stages of viral progeny production when the Gag polyprotein formed. The resulting intracellular accumulation of the Gag polyprotein was followed by inefficient Gag assembly and decreased RNA packaging. The disruption of CD81 tetraspanin membrane remodelling is proposed as a significant marker of defective HIV replication. Taken together, these findings could influence future strategies for using the altered scaffold protein as an anti-HIV-1 molecule.

Author Contributions: C.T.; Conceptualization, S.M., R.M., P.C., K.C.; Investigation, R.M., P.C.; STED experiment, S.M., R.M., P.C., C.T.; Methodology, S.M.; original draft preparation, C.T., R.M., P.C., K.S.,
W.T., K.C.; writing—review and editing C.T.; Supervision, C.T.; funding acquisition. All authors read and approved the final manuscript.

Funding: This research work was supported by the Distinguished Research Professor Grant (NRCT 808/2563) of the National Research Council of Thailand, the Office of National Higher Education Science Research and Innovation Policy Council (NXPO), Thailand, through the Program Management Unit for Competitiveness (PMU C), contract number C10F630145, the Program Management Unit for Human Resources and Institutional Development, Research and Innovation (grant number B05F630102), the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation (Grant No. RGNS 63-067), Fundamental Fund, Ministry of Higher Education, Science, Research and Innovation (Grant No. R00030097).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article.

Acknowledgments: We would like to thank Marylene Mougel of IRIM-CNRS (France), for welcoming S.M. in her team in Montpellier where S.M. was trained in RNA extraction and analysis. We are really grateful to all members of Mougel’s team for many kind advices. We appreciate National Nanotechnology Center, National Science and Technology Development Agency for operating STED confocal microscopy. We would like to grateful thank to Biomedical Technology Research Center (BMTRC) for operating flow cytometer.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ono, A.; Ablan, S.D.; Lockett, S.J.; Nagashima, K.; Freed, E.O. Phosphatidylinositol (4, 5) bisphosphate regulates HIV-1 gag targeting to the plasma membrane. Proc. Natl. Acad. Sci. USA 2004, 101, 14889–14894. [CrossRef] [PubMed]
2. Saad, J.S.; Miller, J.; Tai, J.; Kim, A.; Chanam, R.H.; Summers, M.E. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl. Acad. Sci. USA 2006, 103, 11364–11369. [CrossRef] [PubMed]
3. Ivanchenko, S.; Godinez, W.J.; Lampe, M.; Krausslich, H.G.; Eils, R.; Rohr, K.; Bräuchle, C.; Müller, B.; Lamb, D.C. Dynamics of HIV-1 Assembly and Release. PLoS Pathog. 2009, 5, e1000652. [CrossRef]
4. Ferrer, M.; Clerte, C.; Chamontin, C.; Basyuk, E.; Laine, S.; Hottin, J.; Bertrand, E.; Margeat, E.; Mougel, M. Imaging HIV-1 RNA dimerization in cells by multicolor super-resolution and fluctuation microscopies. Nucleic Acids Res. 2016, 44, 7922–7934. [CrossRef]
5. Briggs, J.A.; Simon, M.N.; Gross, I.; Kräusslich, H.G.; Fuller, S.D.; Vogt, V.M.; Johnson, M.C. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 2004, 11, 672–675. [CrossRef] [PubMed]
6. Bachrach, E.; Dreja, H.; Lin, Y.L.; Mettling, C.; Pinet, V.; Corbeau, P.; Piechaczyk, M. Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. Virology 2005, 332, 418–429. [CrossRef]
7. Votteler, J.; Sundquist, W.I. Virus budding and the ESCRT pathway. Cell Host Microbe. 2013, 14, 232–241. [CrossRef]
8. Freed, E.O. HIV-1 assembly, release and maturation. Nat. Rev. Microbiol. 2015, 13, 484–496. [CrossRef]
9. Didierlaurent, L.; Racine, P.J.; Houzet, L.; Chamontin, C.; Berkhout, B.; Mougel, M. Role of HIV-1 RNA and protein determinants for the selective packaging of spliced and unspliced viral RNA and host U6 and 7SL RNA in virus particles. Nucleic Acids Res. 2011, 39, 8915–8927. [CrossRef]
10. Abd El-Wahab, E.W.; Smyth, R.P.; Mailler, E.; Bernacchi, S.; Vivet-Boudou, V.; Hijnen, M.; Jossinet, F.; Mak, J.; Paillart, J.C.; Marquet, R. Specific recognition of the HIV-1 genomic RNA by the Gag precursor. Nat. Commun. 2014, 5, 4304. [CrossRef]
11. Houzet, L.; Paillart, J.C.; Smagulova, F.; Maurel, S.; Morichaud, Z.; Marquet, R.; Mougel, M. HIV controls the selective packaging of genomic, spliced viral and cellular RNAs into virions through different mechanisms. Nucleic Acids Res. 2007, 35, 2695–2704. [CrossRef] [PubMed]
12. Onafuwa-Nuga, A.A.; Telesnitsky, A.; King, S.R. 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. RNA 2006, 12, 542–546. [CrossRef] [PubMed]
13. Dahmane, S.; Doucet, C.; Le Gall, A.; Chamontin, C.; Dosset, P.; Murcy, F.; Fernandez, L.; Salas, D.; Rubinstein, E.; Mougel, M.; et al. Nanoscale organization of tetrasmains during HIV-1 budding by correlative dSTORM/AFM. Nanoscale 2019, 11, 6036–6044. [CrossRef] [PubMed]
14. Charrin, S.; Manié, S.; Billard, M.; Ashman, L.; Gerlier, D.; Boucheix, C.; Rubinstein, E. Multiple levels of interactions within the tetrasmain web. Biochem. Biophys. Res. Commun. 2003, 304, 107–112. [CrossRef]
15. Stipp, C.S.; Kolesnikova, T.V.; Hemler, M.E. Functional domains in tetrasmain proteins. Trends Biochem. Sci. 2003, 28, 106–112. [CrossRef]
16. Charrin, S.; Le Naour, F.; Silvie, O.; Milhiet, P.E.; Boucheix, C.; Rubinstein, E. Lateral organization of membrane proteins: Tetrasmains spin their web. Biochem. J. 2009, 420, 133–154. [CrossRef]
Viruses 2022, 14, 824

17. Hemler, M.E. Tetraspanin functions and associated domains. Nat. Rev. Mol. Cell Biol. 2005, 6, 801–811. [CrossRef]
18. Grigorov, B.; Attail-Audenis, V.; Perugi, F.; Nedelec, M.; Watson, S.; Pique, C.; Darlix, J.L.; Conjeaud, H.; Muriaux, D. A role for CD81 on the late steps of HIV-1 replication in a chronically infected T cell line. Retrovirology 2009, 6, 28. [CrossRef]
19. Kremetssov, D.N.; Rassam, P.; Margeat, E.; Roy, N.H.; Schneider-Schaullies, J.; Milhiet, P.E.; Thali, M. HIV-1 assembly differentially alters dynamics and partitioning of tetraspanins and raft components. Traffic 2010, 11, 1401–1414. [CrossRef]
20. Deneka, M.; Pelchen-Matthews, A.; Byland, R.; Ruiz-Mateos, E.; Marsh, M. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J. Cell Biol. 2007, 177, 329–341. [CrossRef]
21. Gaudin, R.; Berre, S.; Cunha de Alencar, B.; Decalf, J.; Schindler, M.; Gobert, F.X.; Jouve, M.; Bénarocq, F. Dynamics of HIV-containing compartments in macrophages reveal sequestration of virions and transient surface connections. PLoS ONE 2013, 8, e69450. [CrossRef] [PubMed]
22. Garcia, E.; Fion, M.; Pelchen-Matthews, A.; Collinson, L.; Arrighi, J.F.; Blot, G.; Leuba, F.; Escola, J.M.; Demaurex, N.; Marsh, M.; et al. HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. Traffic 2005, 6, 488–501. [CrossRef] [PubMed]
23. Chupradit, K.; Moonmuang, S.; Nangola, S.; Kitidee, K.; Yasamut, U.; Mougel, M.; Tayapiwatana, C. Current Peptide and Protein-Protein Interactions: Insight from Molecular Dynamics Simulations and Nanoparticle Tracking Analysis. Molecules 2015, 20, 5696. [CrossRef]
24. Li, G.; Verheyen, J.; Rhee, S.Y.; Voet, A.; Vandamme, A.M.; Theys, K. Functional conservation of HIV-1 Gag: Implications for rational drug design. Retrovirology 2013, 10, 126. [CrossRef] [PubMed]
25. Tang, C.; Loeliger, E.; Kinde, I.; Kyere, S.; Mayo, K.; Barklis, E.; Sun, Y.; Huang, M.; Summers, M.F. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 2007, 327, 1013–1020. [CrossRef]
26. Lemke, C.T.; Titolo, S.; von Schwedler, U.; Goudreau, N.; Mercier, J.F.; Wardrop, E.; Faucher, A.M.; Coulombe, R.; Banik, S.S.R.; Fader, L. Distinct effects of two HIV-1 assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J. Virol. 2012, 86, 6643–6655. [CrossRef]
27. Blair, W.S.; Pickford, C.; Irving, S.L.; Brown, D.G.; Anderson, M.; Bazin, R.; Cao, J.; Ciaramelle, G.; Isaacson, J.; Murray, E.; Patrick, A.K.; Peng, Q.; Perros, M.; et al. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob. Agents Chemother. 2011, 55, 3065–3073. [CrossRef] [PubMed]
28. Aiken, C.; Chen, C.H. Betaulinic acid derivatives as HIV-1 antivirals. ACS Chem. Biol. 2015, 10, 1512–1523. [CrossRef] [PubMed]
29. Sticht, J.; Humbert, M.; Findlow, S.; Bodem, J.; Müller, B.; Dietrich, U.; Werner, J.; Kräusslich, H.G. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 2005, 12, 671–677. [CrossRef]
30. Garzon, M.T.; Lidon-Moya, M.C.; Barrera, F.N.; Prieto, A.; Gómez, J.; Mateu, M.G.; Neira, J.L. The dimerization domain of the HIV-1 capsid protein binds a capsid protein-derived peptide: A biophysical characterization. Protein Sci. 2004, 13, 1512–1523. [CrossRef] [PubMed]
31. Lampel, A.; Bram, Y.; Ezer, A.; Shaltiel-Kario, R.; Saad, J.S.; Bacharach, E.; Gazit, E. Targeting the Early Step of Building Block Candidates Challenging Viral Capsid Assembly. ACS Chem. Biol. 2015, 10, 1785–1790. [CrossRef] [PubMed]
32. Thenin-Houssier, S.; de Vera, I.M.; Pedro-Rosa, L.; Brady, A.; Richard, A.; Konnick, B.; Opp, S.; Buffone, C.; Kota, S.; Billack, B.; et al. Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrob. Agents Chemother. 2016, 60, 2195–2208. [CrossRef] [PubMed]
33. Urano, E.; Timilsina, U.; Kaplan, J.A.; Ablan, S.; Ghimire, D.; Pham, P.; Kuruppu, N.; Mandt, R.; Durell, S.R.; Nitz, T.J.; et al. Resistance to Second-Generation HIV-1 Maturation Inhibitors. J. Virol. 2019, 93, e02017-18. [CrossRef] [PubMed]
34. Aiken, C.; Chen, C.H. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol. Med. 2015, 15, 10–11. [CrossRef] [PubMed]
35. Lu, W.; Salzwedel, K.; Wang, D.; Chakravarty, S.; Freed, E.O.; Wild, C.T.; Li, F. A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. Antimicrob. Agents Chemother. 2011, 55, 3324–3329. [CrossRef] [PubMed]
36. Blair, W.S.; Cao, J.; Fok-Seang, J.; Griffin, P.; Isaacson, J.; Jackson, R.L.; Murray, E.; Patrick, A.K.; Peng, Q.; Perros, M.; et al. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob. Agents Chemother. 2009, 53, 5080–5087. [CrossRef] [PubMed]
37. Khamkawin, W.; Saaon, S.; Nangola, S.; Chupradit, K.; Sakkhachornphop, S.; Hadpech, S.; Onlamoon, N.; Ansari, A.A.; Byrareddy, S.N.; Boulanger, P.; et al. Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly. Mol. Ther. Nucleic Acids. 2015, 4, e249. [CrossRef]
38. Nangola, S.; Urvoas, A.; Valero-Lepiniec, M.; Khamkawin, W.; Sakkhachornphop, S.; Hong, S.S.; Boulanger, P.; Minard, P.; Tayapiwatana, C. Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polypeptide. Retrovirology 2012, 9, 17. [CrossRef] [PubMed]
39. Sakkhachornphop, S.; Hadpech, S.; Wisitponchai, T.; Panto, C.; Kantamala, D.; Utaipat, U.; Praparatpananjan, J.; Kotarathitithum, W.; Taejaroenkul, S.; Yasamut, U.; et al. Broad-Spectrum Antiviral Activity of an Ankyrin Repeat Protein on Viral Assembly against Chimeric NL4-3 Viruses Carrying Gag/PR Derived from Circulating Strains among Northern Thai Patients. Viruses 2018, 10, 625. [CrossRef] [PubMed]
40. Chong, W.L.; Chupradit, K.; Chin, S.P.; Khoo, M.M.; Khor, S.M.; Tayapiwatana, C.; Nimmanpipup, P.; Thongkum, W.; Lee, V.S. Protein-Protein Interactions: Insight from Molecular Dynamics Simulations and Nanoparticle Tracking Analysis. Molecules 2021, 26, 5696. [CrossRef] [PubMed]
41. Chamontin, C.; Rassam, P.; Ferrer, M.; Racine, P.J.; Neyret, A.; Lainé, S.; Milhiet, P.-E.; Mougel, M. HIV-1 nucleocapsid and ESCRT-component Tsg101 interplay prevents HIV from turning into a DNA-containing virus. *Nucleic Acids Res.* 2015, 43, 336–347. [CrossRef] [PubMed]

42. Sornsuwan, K.; Thongkhum, W.; Pamonsupornwichit, T.; Carraway, T.S.; Soponpong, S.; Sakkhachornphop, S.; Tayapiwattana, C.; Yasamut, U. Performance of Affinity-Improved DARpin Targeting HIV Capsid Domain in Interference of Viral Progeny Production. *Biomolecules* 2021, 11, 1437. [CrossRef] [PubMed]

43. Kitidee, K.; Khamkaewin, W.; Thongkum, W.; Tawon, Y.; Cressey, T.R.; Jevprasesphant, R.; Kasinrerk, W.; Tayapiwatana, C. Expedition screening for HIV-1 protease inhibitors using a simplified immunochromatographic assay. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2016, 1021, 153–158. [CrossRef] [PubMed]

44. Mariani, C.; Desdouits, M.; Favard, C.; Benaroch, P.; Muriaux, D.M. Role of Gag and lipids during HIV-1 assembly in CD4+ T cells and macrophages. *Front. Microbiol.* 2014, 5, 312. [CrossRef]

45. Lichtman, J.W.; Conchello, J.A. Fluorescence microscopy. *Nat. Methods* 2005, 2, 910–919. [CrossRef] [PubMed]

46. Chojnacki, J.; Staudt, T.; Glass, B.; Bingen, P.; Engelhardt, J.; Anders, M.; Schneider, J.; Müller, B.; Hell, S.W.; Kräusslich, H.G. Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. *Science* 2012, 338, 524–528. [CrossRef]

47. Favard, C.; Chojnacki, J.; Merida, P.; Yandrapalli, N.; Mak, J.; Eggeling, C.; Muriaux, D. HIV-1 Gag specifically restricts PI(4, 5)P2 and cholesterol mobility in living cells creating a nanodomain platform for virus assembly. *Sci. Adv.* 2019, 5, eaaw8651. [CrossRef]

48. Hurley, J.H.; Emr, S.D. The ESCRT complexes: Structure and mechanism of a membrane-trafficking network. *Annu. Rev. Biophys. Biomol. Struct.* 2006, 35, 277–298. [CrossRef]

49. Dick, A.; Cocklin, S. Recent Advances in HIV Inhibitor Design and Development. *Molecules* 2020, 25, 1687. [CrossRef]

50. Hadpech, S.; Nangola, S.; Chupradit, K.; Fanhchaksai, K.; Furnon, W.; Urvoas, A.; Valerio-Lepiniec, M.; Minard, P.; Boulanger, P.; Hong, S.S.; et al. Alpha-helicaloid HEAT-like Repeat Proteins (alphaRep) Selected as Interactors of HIV-1 Nucleocapsid Negatively Interfere with Viral Genome Packaging and Virus Maturation. *Sci Rep.* 2017, 7, 16335. [CrossRef]

51. Kleinpeter, A.B.; Freed, E.O. HIV-1 Maturation: Lessons Learned from Inhibitors. *Viruses* 2020, 12, 940. [CrossRef] [PubMed]

52. Yant, S.R.; Mulato, A.; Hansen, D.; Tse, W.C.; Niedziela-Majka, A.; Zhang, J.R.; Stepan, G.J.; Jin, D.; Wong, M.H.; Perreira, J.M.; et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. *Nat. Med.* 2019, 25, 1377–1384. [CrossRef] [PubMed]

53. Datta, S.A.; Heinrich, F.; Raghunandan, S.; Krueger, S.; Curtis, J.E.; Rein, A.; Nanda, H. HIV-1 Gag extension: Conformational changes require simultaneous interaction with membrane and nucleic acid. *J. Mol. Biol.* 2011, 406, 205–214. [CrossRef]

54. Ferrer, M.; Henriot, S.; Chamontin, C.; Lainé, S.; Mougel, M. From Cells to Virus Particles: Quantitative Methods to Monitor RNA Packaging. *Viruses* 2016, 8, 239. [CrossRef]

55. Duchon, A.; Santos, S.; Chen, J.; Brown, M.; Nikolitchik, O.A.; Tai, S.; Chao, J.A.; Freed, E.O.; Pathak, V.K.; Hu, W.S. Plasma Membrane Anchoring and Gag-Gag Multimerization on Viral RNA Are Critical Properties of HIV-1 Gag Required To Mediate Efficient Genome Packaging. *Mbio* 2021, 12, e0325421. [CrossRef]

56. Keene, S.E.; King, S.R.; Telesnitsky, A. 7SL RNA is retained in HIV-1 minimal virus-like particles as an S-domain fragment. *J. Virol.* 2010, 84, 9070–9077. [CrossRef] [PubMed]

57. Lalande, M.S.; Sundquist, W.J. How HIV finds the door. *Proc. Natl. Acad. Sci. USA* 2012, 109, 18631–18632. [CrossRef] [PubMed]

58. Jolly, C.; Sattentau, Q.J. Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains. *J. Virol.* 2007, 81, 7873–7884. [CrossRef]

59. Yáñez-Mó, M.; Barreiro, O.; Gordon-Alonso, M.; Sala-Valdés, M.; Sánchez-Madrid, F. Tetraspanin-enriched microdomains: A functional unit in cell plasma membranes. *Trends Cell Biol.* 2009, 19, 434–446. [CrossRef]

60. Suárez, H.; Rocha-Perugini, V.; Álvarez, S.; Yáñez-Mó, M. Tetraspanins, Another Piece in the HIV-1 Replication Puzzle. *Front. Immunol.* 2018, 9, 1811. [CrossRef]

61. Krementsov, D.N.; Weng, J.; Lambelé, M.; Roy, N.H.; Thali, M. Tetraspanins regulate cell-to-cell transmission of HIV-1. *Retrovirology* 2009, 6, 64. [CrossRef] [PubMed]

62. Gordon-Alonso, M.; Yáñez-Mó, M.; Barreiro, O.; Álvarez, S.; Muñoz-Fernández, M.A.; Valenzuela-Fernández, A.; Sánchez-Madrid, F. Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion. *J. Immunol.* 2006, 177, 5129–5137. [CrossRef] [PubMed]